Ligand id: 7335

Name: nivolumab

Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2014), EMA (2015))
International Nonproprietary Names
INN number INN
9623 nivolumab
BMS-936558 | MDX-1106 | ONO-4538 | Opdivo®
Nivolumab is an IgG4 kappa immunoglobulin that is selective for PD-1, an immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells [12]. This monoclonal is produced in Chinese hamster ovary cells by recombinant DNA technology. Nivolumab is an immuno-oncology drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Sequence analysis of the light and heavy chain variable region peptides of nivolumab shows exact matches with claimed peptide sequences of monoclonal 5C4 contained in patent WO2006121168 [10].
Database Links
Specialist databases
IMGT/mAb-DB 424
Other databases
GtoPdb PubChem SID 178103907
PubChem SID 178103907
Search PubMed clinical trials nivolumab
Search PubMed titles nivolumab
Search PubMed titles/abstracts nivolumab
Wikipedia nivolumab